Significant reduction in PANSS total score at week 6 (n=607)1

  • Both doses of SECUADO® were also statistically superior to placebo for Clinical Global Impressions – Severity (CGI-S)1
  • An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and/or race1

The efficacy of SECUADO® was evaluated in a 6-week, fixed-dose, randomized, double-blind, placebo-controlled trial (Study 1; NCT 02876900) of adult patients who met DSM-IV® criteria for schizophrenia. The PANSS and CGI-S rating scales were used as the primary and key secondary efficacy measures, respectively, for assessing psychiatric signs and symptoms in each trial.1

PANSS is a 30-item scale that measures positive symptoms of schizophrenia (7 items), negative symptoms of schizophrenia (7 items), and general psychopathology (16 items), each rated on a scale of 1 (absent) to 7 (extreme); total PANSS scores range from 30 to 210.

CGI-S is a validated clinician-related scale that measures the patient’s current illness state and overall clinical state on a 1-point (normal, not at all ill) to 7-point (extremely ill) scale, based on the rater’s total clinical experience with this population.1

DSM-IV® = Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); LS = least squares; PANSS = Positive and Negative Syndrome Scale; SE = standard error.

DSM-IV® is a registered trademark of the American Psychiatric Association.

You are now leaving the SECUADO® (asenapine) transdermal system website and moving to an external website independently operated and not managed by Noven

The site you are about to enter is intended specifically for US healthcare professionals.

Click continue if you are a US healthcare professional.